Watabe T, Mukai K, Naka S, Sasaki H, et al. First-in-Human Study of [(211)At]NaAt as Targeted alpha-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). J Nucl Med 2025 Sep 25:jnumed.125.270810. doi: 10.2967/jnumed.125.270810.
PMID: 40998730